Cysteamine Decreases Prolactin Responsiveness to Thyrotropin‐Releasing Hormone in Normal Men

Cysteamine depletes pituitary and plasma prolactin in rats. It acts through a nondopaminergic mechanism to alter both iramu-noactive and bioactive prolactin. The effect of cysteamine on prolactin secretion is reported in normal men. Six normal subjects received a control thyrotropin-releasing hormone (TRH) test at 0900 using 200 μg TRH intravenously; serum prolactin and TSH were measured at −10, 0, 10, 20, 30, 60, and 90 min after administration of TRH. Serum calcium and parathyroid hormones levels were measured at −10 min. Seven or more days later, they received cysteamine hydro-chloride 15 mg/kg body weight orally every 6 hours for 5 doses. One hour after the last dose, the TRH test was repeated. Peak serum prolactin levels following TRH, prolactin levels at the 10-min time point, and total area from 0 to 30 min under the prolactin secretory curve were significantly decreased by cysteamine administration. TSH levels were unchanged. Serum calcium levels were significantly decreased by cysteamine administration, but parathyroid hormone levels were unchanged. It was concluded that cysteamine reduced TRH-stimulated prolactin secretion. Cysteamine also decreases serum calcium levels and suppresses the anticipated rise in serum parathyroid hormone levels. These effects on serum calcium and parathyroid hormone are similar to those previously shown for WR2721, another sulfhydryl compound. Cysteamine should be further considered as an alternative drug in the treatment of hyperprolactinemia and as a therapeutic agent for hypercalcemia.

[1]  W. Gahl,et al.  Blunted prolactin response to thyrotropin-releasing hormone stimulation in cystinotic children receiving cysteamine. , 1985, The Journal of clinical endocrinology and metabolism.

[2]  V. Beral,et al.  PREGNANCY OUTCOME IN INSULIN-DEPENDENT DIABETICS WITH THYROID DISEASE OR PERNICIOUS ANAEMIA , 1984, The Lancet.

[3]  J. Scammell,et al.  Depletion of pituitary prolactin by cysteamine is due to loss of immunological activity. , 1984, Endocrinology.

[4]  S. Shin,et al.  Cysteamine acts immediately to inhibit prolactin release and induce cellular changes in estradiol-primed male rats. , 1984, Neuroendocrinology.

[5]  W. Millard,et al.  Cysteamine induces depletion of both immunological and biological prolactin activity in the anterior pituitary and blood of the rat. , 1983, Endocrinology.

[6]  S. Goldfarb,et al.  Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). , 1983, The New England journal of medicine.

[7]  M. Lorenson,et al.  Detectability of pituitary PRL and GH by immunoassay is increased by thiols and suppressed by divalent cations. , 1983, Endocrinology.

[8]  L. Grouse,et al.  Cysteamine Blocks Somatostatin Secretion Without Altering the Course of Insulin or Glucagon Release: A New Model for the Study of Islet Function , 1983, Diabetes.

[9]  J. B. Martin,et al.  The effects of cysteamine on thyrotropin and immunoreactive beta-endorphin secretion in the rat. , 1983, Endocrinology.

[10]  J. B. Martin,et al.  Cysteamine: a potent and specific depletor of pituitary prolactin. , 1982, Science.

[11]  S. Szabó,et al.  Selective depletion of somatostatin in rat brain by cysteamine , 1982, Brain Research.

[12]  A. F. Stewart,et al.  Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. , 1982, The New England journal of medicine.

[13]  J. B. Martin,et al.  Cysteamine reduces serum gonadotropin concentrations in adult male rats. , 1982, Life sciences.

[14]  S. Szabó,et al.  Somatostatin in rat tissues is depleted by cysteamine administration. , 1981, Endocrinology.

[15]  J. Schulman,et al.  Pantetheinase Activity and Cysteamine Content in Cystinotic and Normal Fibroblasts and Leukocytes , 1981, Pediatric Research.

[16]  A. Brodrick,et al.  THE STABILITY OF AN ORAL LIQUID FORMULATION OF CYSTEAMINE , 1981, Journal of clinical and hospital pharmacy.

[17]  M. Yudkoff,et al.  Effects of cysteamine therapy in nephropathic cystinosis. , 1981, The New England journal of medicine.

[18]  F. Maloof,et al.  Metabolic clearance and production rates of prolactin in man. , 1979, The Journal of clinical investigation.

[19]  P. Sönksen,et al.  BROMOCRIPTINE SUPPRESSION OF TRH‐STIMULATED PROLACTIN AND THYROTROPHIN RELEASE AND ACCOMPANYING INHIBITION OF BROMOCRIPTINE INDUCED GROWTH HORMONE RELEASE BY TRH IN NORMAL MAN , 1979, Clinical endocrinology.

[20]  B. Weintraub,et al.  The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. , 1976, The Journal of clinical endocrinology and metabolism.

[21]  G. Sutherland,et al.  CYSTEAMINE, METHIONINE, AND PENICILLAMINE IN THE TREATMENT OF PARACETAMOL POISONING , 1976, The Lancet.

[22]  B. Weintraub,et al.  Suppression of pituitary TSH secretion in the patient with a hyperfunctioning thyroid nodule. , 1973, The Journal of clinical investigation.

[23]  J. Schulman,et al.  Adverse reactions to oral cysteamine use in nephropathic cystinosis. , 1981, Developmental pharmacology and therapeutics.